Temporal trends in the prevalence of albuminuria and reduced eGFR in Japanese patients with type 2 diabetes

  • Nobue Tanaka
  • Yui Yamamoto
  • Yoichi Yokoyama
  • Tomomi Mori
  • Ko Hanai
  • Tetsuya BabazonoEmail author
Original Article


Changes over time have been shown in renal manifestations in individuals with diabetes in the United States; however, whether the trends are shared across ethnicities is unknown. We conducted this single-center serial cross-sectional study to determine temporal changes in albuminuria and reduced kidney function in Japanese patients with type 2 diabetes. This study included adult Japanese patients with type 2 diabetes who first visited our institute between 2004 and 2013. Temporal changes during the 10 years in the frequency of albuminuria ( ≥ 30 mg/g creatinine) and reduced eGFR ( < 60 mL/min/1.73 m2) were analyzed using the univariate and multivariate logistic regression analyses and Granger causality test. 5331 Japanese patients with type 2 diabetes, 1892 women and 3439 men, with the mean age of 56 ± 13 years, were studied. There was no change in the prevalence of albuminuria in the univariate analysis; however, a significantly decreasing trend was observed after adjustment for several covariates. On the other hand, patients with reduced eGFR significantly increased over time, although the statistical significance disappeared after adjustment for the covariates, including levels of serum uric acid and hemoglobin and use of renin–angiotensin inhibitors. The Granger causality test showed that time series for use of RAS inhibitors and BMI had a causative role in time series for reduced eGFR. In conclusion, prevalence of albuminuria decreased and that of reduced eGFR remained stable after adjustment for clinical characteristics in Japanese patients with type 2 diabetes during the last decade.


Albuminuria eGFR Type 2 diabetes Granger causality 


Author contributions

NT designed the study, collected the data, performed the statistical analyses, researched data, and wrote the manuscript. YYa, YYo, TM, and KH substantially contributed to collection and interpretation of data. TB is the guarantor of this work, had full access to all the data in the study, performed the statistical analyses in part, reviewed/edited the manuscript, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Compliance with ethical standards

Conflicts of interest

The authors have nothing to declare.

Human rights statement

The present study was conducted as a part of the Prospective Cohort Study Elucidating Factors Associated with the Pathogenesis, Prognosis, and Prognosis of Diabetic Nephropathy conducted in Diabetes Center, Tokyo Women’s Medical University, the protocol of which was approved by the Ethics Committee of Tokyo Women’s Medical University School of Medicine (Approval No. 1584)

Informed consent

Since this was an observational but not a prospective intervention study, the Ethics Committee provided a waiver of informed consent.


  1. 1.
    Hasslacher CH, Ritz E, Wahl P, et al. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transpl. 1989;4:859–63.CrossRefGoogle Scholar
  2. 2.
    Yokoyama H, Okudaira M, Otani T, et al. Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 2000;58:302–11.CrossRefPubMedGoogle Scholar
  3. 3.
    Pugh JA, Medina R, Ramirez M. Comparison of the course to end-stage renal disease of type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic nephropathy. Diabetologia. 1993;36:1094–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Ohta M, Babazono T, Uchigata Y, et al. Comparison of the prevalence of chronic kidney disease in Japanese patients with type 1 and type 2 diabetes. Diabet Med. 2010;27:1017–23.CrossRefPubMedGoogle Scholar
  5. 5.
    Mongensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes. 1983; 32 (Suppl 2): 64-78.CrossRefGoogle Scholar
  6. 6.
    Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective diabetes study 74. Diabetes. 2006; 55: 1832-8.CrossRefPubMedGoogle Scholar
  7. 7.
    Yokoyama H, Sone H, Oishi M, et al. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan diabetes clinical data management study (JDDM 15). Nephrol Dial Transpl. 2009;24:1212–9.CrossRefGoogle Scholar
  8. 8.
    Kramer CK, Leitão CB, Pinto LC, et al. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care. 2007;30:1998–2000.CrossRefPubMedGoogle Scholar
  9. 9.
    Takagi M, Babazono T, Uchigata Y. Differences in risk factors for the onset of albuminuria and decrease in glomerular filtration rate in people with Type 2 diabetes mellitus: implications for the pathogenesis of diabetic kidney disease. Diabet Med. 2015;32:1354–60.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kramer HJ, Nguyen QD, Curhan G, et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289:3273–7.CrossRefPubMedGoogle Scholar
  11. 11.
    de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016;316:602–10.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kume S, Araki S, Ugi S, et al. Secular changes in manifestations of kidney disease among Japanese adults with type 2 diabetes, 1996–2014. J Diabetes Investig. 2018 Nov 19. Scholar
  14. 14.
    Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMedGoogle Scholar
  15. 15.
    Granger CWJ. Investigation causal relations by econometric models and cross-spectral methods. Econometrica. 1969;37:424–38.CrossRefGoogle Scholar
  16. 16.
    Stokes PA, Purdon PL. A study of problems encountered in granger causality analysis from a neuroscience perspective. Proc Natl Acad Sci USA. 2017;114:E7063–E70727072.CrossRefPubMedGoogle Scholar
  17. 17.
    Anderson S, Meier TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest. 1985;76:612–9.CrossRefGoogle Scholar
  18. 18.
    Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 1986;77:1993–2000.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Standards of medical care in diabetes–2015: summary of revisions. Diabetes Care. 2015; 38(Suppl 1):S4.Google Scholar
  20. 20.
    Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3–15.CrossRefPubMedGoogle Scholar
  21. 21.
    Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014;37:253–390.CrossRefPubMedGoogle Scholar
  22. 22.
    MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet. 2001;357:455–62.CrossRefPubMedGoogle Scholar
  23. 23.
    Suissa S, Hutchinson T, Brophy JM, et al. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 2006;69:913–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study. BMJ. 2017;356:j791.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008;75:S13–S1616.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhu P, Liu Y, Han L, et al. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. PLoS ONE. 2014;9:e100801.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hanai K, Tauchi E, Nishiwaki Y, et al. Effects of uric acid on kidney function decline differ depending on baseline kidney function in type 2 diabetic patients. Nephrol Dial Transplant. 2018 Scholar
  28. 28.
    Babazono T, Hanai K, Suzuki K, et al. Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia. 2006;49:1387–93.CrossRefPubMedGoogle Scholar
  29. 29.
    Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004;66:1131–8.CrossRefPubMedGoogle Scholar
  30. 30.
    UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53.CrossRefGoogle Scholar
  31. 31.
    Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Zoungas S, Arima H, Gerstein HC. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:431–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Babazono T, Takahashi C, Iwamoto Y. Definition of microalbuminuria in first-morning and random spot urine in diabetic patients. Diabetes Care. 2004;27:1838–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Davey SG, Ebrahim S. ’Mendelian randomization’: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1–22.CrossRefGoogle Scholar

Copyright information

© The Japan Diabetes Society 2019

Authors and Affiliations

  1. 1.Department of Medicine, Diabetes CenterTokyo Women’s Medical University School of MedicineTokyoJapan

Personalised recommendations